Brief: FDA Approves Expanded Indication For Avtozma® Intravenous Formulation In Cytokine Release Syndrome
06/08/2025 13:41
Aug 6 (Reuters) - Celltrion Inc 068270.KS: FDA APPROVES EXPANDED INDICATION FOR AVTOZMA® (TOCILIZUMAB-ANOH) INTRAVENOUS (IV) FORMULATION IN CYTOKINE RELEASE SYNDROME (CRS) Source text: ID:nPn8MVwVqa Further company coverage: 068270.KS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won